PMAM
INO icon

Picton Mahoney Asset Management’s Inovio Pharmaceuticals INO Stock Holding History

Picton Mahoney Asset Management’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6,215
Closed -$9K – 1076
2025
Q1 		$9K Buy
6,215
+4,292
+223% +$8.61K ﹤0.01% 629
2024
Q4 		$4K Buy
+1,923
New +$8.51K ﹤0.01% 574

Other funds holding INO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Picton Mahoney Asset Management's INO Position: Q2 2025 in Review

Picton Mahoney Asset Management sold out of Inovio Pharmaceuticals (INO) in Q2 2025, closing a stake of 6,215 shares — an estimated $9K sold.

Picton Mahoney Asset Management first reported a position in INO in Q4 2024 and held it in 2 quarters. The position peaked at $9K in Q1 2025. 103 funds tracked by Wall St. Rank hold INO as of Q2 2025.

  • Picton Mahoney Asset Management reported no remaining Inovio Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Picton Mahoney Asset Management sold 6,215 Inovio Pharmaceuticals shares in Q2 2025, an estimated $9K.
  • Picton Mahoney Asset Management first reported a position in Inovio Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Picton Mahoney Asset Management's Inovio Pharmaceuticals position peaked at $9K in Q1 2025.
  • 103 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2025.

Based on Picton Mahoney Asset Management's 13F filing for Q2 2025, filed 12 Aug 2025.